Accretion Nutraveda Limited is a nutraceutical and wellness-focused company engaged in the manufacturing and marketing of health supplements, herbal formulations, and functional nutrition products. The company earns revenue through B2B and B2C sales, supplying branded and contract-manufactured products. Its offerings are used for daily nutrition, immunity support, lifestyle health management, and preventive healthcare, catering to both domestic and export markets.

The Company is led by Promoter, i.e.,MR. MAYUR POPATLAL SOJITRA, MR. ANKURKUMAR SHANTILAL PATEL, MR. PARASKUMAR VINUBHAI PARMAR, MR. HARDIK MUKUNDBHAI PRAJAPATI, MR. HARSHAD NANUBHAI RATHOD & MR. VIVEK ASHOK KUMAR PATEL

The Revenues from operations for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 1,406.55 Lakh, ₹ 1,605.55 Lakh, ₹ 519.68 Lakh, and ₹ 307.14 Lakh, The EBITDA for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 328.55 Lakh, ₹ 364.66 Lakh, ₹ 120.60 Lakh, and ₹ 59.12 Lakh, The Profit after Tax for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 233.28 Lakh, ₹ 261.28 Lakh, ₹ 82.19 Lakh, and ₹ 28.06 Lakh, respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue  EPS of ₹ 71.91 and post-issue EPS of ₹ 3.61 for FY25. The pre-issue P/E ratio is 1.79x,while the post-issue P/E ratio is 35.75x against the Industry P/E ratio is 45.14x The company's ROE for FY25 is 81.22% and RoNW is 48.85% The Annualised EPS is ₹ 6.44x and P/E is ₹ 20.02x, These metrics suggest that the IPO is Fully priced.

 
The Grey Market Premium (GMP) of Accretion Nutraveda  showing listing gains of 0%.Given the company's financial performance and the valuation of the IPO, we recommend  Investors to Avoid to the Accretion Nutraveda  Limited. IPO for Listing gain or Long Term Purposes.